Australian Meningococcal Surveillance Programme annual report, 2012
DOI:
https://doi.org/10.33321/cdi.2013.37.34Keywords:
antibiotic resistance, disease surveillance, meningococcal disease, Neisseria meningitidisAbstract
In 2012, there were 208 laboratory-confirmed cases of invasive meningococcal disease (IMD) analysed by the National Neisseria Network, and 222 cases notified to the National Notifiable Diseases Surveillance System, thus laboratory data were available for 93.7% of cases of IMD in Australia in 2012. Isolates of Neisseria meningitidis from 116 invasive cases of meningococcal disease were available for testing, and the phenotype (serogroup, serotype and serosubtype) and/or genotype, and antibiotic susceptibility were determined. Molecular typing was performed for the 92 cases confirmed by nucleic acid amplification testing (NAAT). Typing information was available for 194 of the 208 laboratory confirmed cases and 83% (161 cases) were serogroup B infections, 5.7% (11 cases) were serogroup C infections, 3.6% (11 cases) were serogroup W135, and 7.7% (15 cases) were serogroup Y meningococci. The number of laboratory confirmed IMD cases in 2012 was the lowest since laboratory surveillance data have been reported. Primary and secondary disease peaks were observed in those aged 4 years or less and in adolescents (15–19 years) and young adults (20–24 years), respectively. Serogroup B cases predominated in all age groups and jurisdictions. In 2012, the most common porA genotype circulating in Australia was P1.7-2,4. Serogroup C, W135 and Y cases were numerically low, similar to previous years. Decreased susceptibility to the penicillin group of antibiotics was observed in 81.9% of isolates, and 1 isolate exhibited resistance to penicillin. All isolates remained susceptible to ceftriaxone, ciprofloxacin and rifampicin. Commun Dis Intell 2013;37(3):E224–E232.
Downloads
References
National Neisseria Network. Meningococcal Isolate Surveillance Australia, 1994. Commun Dis Intell 1995;19:286–289.
National Notifiable Diseases Surveillance System. Number of notifications of meningococcal disease (invasive), received from state and territory health authorities in the period 1991 to 2011 and year-to-date notifications for 2012. Accessed on 28 April 2013. Available from: http://www9.health.gov.au/cda/source/Rpt_4.cfm
The Australian Meningococcal Surveillance Programme. Annual report of the Australian Meningococcal Surveillance Programme, 2011. Commun Dis Intell 2012;36(3):E251–E262.
Public Health Laboratory Network. Meningococcal Laboratory Case Definition. Canberra: Australian Government Department of Health. 28 August 2006. Accessed on 28 April 2013. Available from: http://www1.health.gov.au/internet/main/publishing.nsf/Content/cda-phlncd-mening.htm
Tapsall J and members of the National Neisseria Network of Australia. Antimicrobial testing and applications in the pathogenic Neisseria. In: Merlino J, ed. Antimicrobial susceptibility testing: methods and practices with an Australian perspective. Australian Society for Microbiology, Sydney, 2004. pp 175–188.
Gray SJ, Borrow R, Kaczmarski EB. Meningococcal serology. In: Pollard AJ, Martin MCJ, eds. Meningococcal disease methods and protocols. Humana Press, Totawa, New Jersey, 2001 pp 61–87.
Robertson PW, Reinbott P, Duffy Y, Binotto E, Tapsall JW. Confirmation of invasive meningococcal disease by single point estimation of IgM antibody to outer membrane protein of Neisseria meningitidis. Pathology 2001;33(3):375–378.
Lahra MM, Robertson PW, Whybin R, Tapsall JW. Enhanced serological diagnosis of invasive meningococcal disease by determining anti-group C capsule IgM antibody by EIA. Pathology 2005;37(3):239–241.
Maiden MC, Ibarrz-Pavon AB, Urwin R, Gray SJ, Andrews NJ, Clark SC, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis 2008;197(5):737–743.
Shultz TR, Tapsall JW, White PA, Newton PJ. An invasive isolate of Neisseria meningitidis showing decreased susceptibility to quinolones. Antimicrob Agents Chemother 2000;44(4):1116.
Singhal S, Purnapatre KP, Kalia V, Dube S, Nair D, Deb M, et al. Ciprofloxacin-resistant Neisseria meningitidis, Delhi, India. Emerg Infect Dis 2007;13(10):1614–1616.
Centers for Disease Control and Prevention. Emergence of fluoroquinolone-resistant Neisseria meningitidis—Minnesota and North Dakota, 2007–2008. MMWR Morb Mortal Wkly Rep 2008;57(7):173–175.
Shultz TR, White PA, Tapsall JW. In-vitro assessment of the further potential for development of quinolone resistance in Neisseria meningiditis. Antimicrob Agent Chemother 2005;49(5):1753–1760.
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2013 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
